Geòrgia Anguera

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

Alfonso Gómez de Liaño, Nick van Dijk, Guillermo de Velasco et al. · European Urology · 2019 · 62 citations

Medicine, Clinical Sciences, Oncology +15

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Mariona Riudavets, Joaquín Mosquera, Rosario García‐Campelo et al. · Frontiers in Oncology · 2020 · 56 citations · Full text

Pharmacy, Immunology, Oncology +17

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome

Juan María Roldán‐Romero, María Santos, Javier Lanillos et al. · Modern Pathology · 2020 · 55 citations

Medicine, Cancer Biology, Oncology +15

Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration

Ariadna Tibau, Alberto Ocaña, Geòrgia Anguera et al. · JAMA Oncology · 2016 · 32 citations · Full text

Pharmacy, Oncology, Pharmacology +16